Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With… | Phase 2 | suspended | Dec 16, 2020 | Henan Cancer Hospital | Data in analysis | Other (stated, no rule matched) |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell… | Phase 2 | terminated | Aug 7, 2019 | M.D. Anderson Cancer Center | Administratively Complete 75%\<Participants | Other (stated, no rule matched) |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed… | Phase 1 | terminated | Apr 3, 2018 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 / Phase 2 | terminated | May 21, 2021 | University of Maryland, Baltimore | The study was terminated due to FDA withdrawal of the drug and lack of enrollment with available… | Enrollment / accrual |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously… | Phase 2 | terminated | Mar 12, 2019 | Janssen Research & Development, LLC | The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee… | Efficacy / futility |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed… | Phase 1 | terminated | Jul 23, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With…(R/R) | Phase 1 / Phase 2 | terminated | Jun 5, 2020 | Aprea Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | — | terminated | Jul 29, 2021 | Celgene | Slow accrual | Enrollment / accrual |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's… | Phase 1 | terminated | Mar 28, 2019 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With… | Phase 1 / Phase 2 | withdrawn | Aug 3, 2022 | Alfred Chung, MD | Industry sponsor unable to continue support | Other (stated, no rule matched) |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in… | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Celgene | Change in business priorities. | Sponsor / business decision |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Mar 7, 2018 | Roswell Park Cancer Institute | funding ended | Funding |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | — | terminated | Nov 17, 2014 | Fred Hutchinson Cancer Center | Study terminated due to end of funding | Funding |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | Phase 2 | withdrawn | Apr 8, 2024 | Jack Khouri, MD | Funding unavailable | Funding |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With… | Phase 1 / Phase 2 | terminated | Oct 23, 2024 | GlaxoSmithKline | The study was terminated due to lack of efficacy | Efficacy / futility |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia… | Phase 1 | withdrawn | Mar 4, 2021 | M.D. Anderson Cancer Center | 0% Participants | Other (stated, no rule matched) |
| NCT04148742 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have… | Phase 1 / Phase 2 | withdrawn | Nov 1, 2019 | Dizal Pharmaceuticals | Clinical development strategy adjustment, non-safety reason | Safety / toxicity |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in… | Phase 2 | terminated | Jan 7, 2021 | Hackensack Meridian Health | Low Accrual | Enrollment / accrual |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple… | — | terminated | May 4, 2016 | Takeda | This study was stopped 3 years early due to business reprioritization within Takeda | Sponsor / business decision |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Phase 1 | withdrawn | Aug 9, 2019 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04895917 | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis(DarPAL) | Phase 2 | terminated | May 20, 2021 | Fondazione IRCCS Policlinico San Matteo di Pavia | low patient enrollment rate | Enrollment / accrual |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic(IFM2014-01) | Phase 2 | terminated | Sep 25, 2018 | Intergroupe Francophone du Myelome | Recruitment issue, 26 patients enrolled instead of 70 initially planned | Enrollment / accrual |
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Phase 1 / Phase 2 | terminated | Nov 5, 2019 | Multiple Myeloma Research Consortium | Pharmaceutical support has been discontinued. | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | terminated | Aug 18, 2020 | Deepa Jagadeesh | Funding unavailable | Funding |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | Phase 1 | terminated | Aug 17, 2018 | Dana-Farber Cancer Institute | Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients… | Drug supply |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory… | Phase 2 | terminated | Apr 10, 2015 | Janssen Research & Development, LLC | DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort… | Efficacy / futility |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab… | Phase 1 | withdrawn | Apr 19, 2016 | Janssen Research & Development, LLC | not stated | Not stated |
| NCT03180853 | Multiple Myeloma Patient Registry | — | terminated | Jun 8, 2017 | Janssen Scientific Affairs, LLC | Completion of study in orig timeframe not feasible considering evolving treatments for MM in US. | Other (stated, no rule matched) |
| NCT03061305 | Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors | — | terminated | Feb 23, 2017 | Strata Oncology | Sponsor's discretion to termination due to business decision. | Sponsor / business decision |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory…(AcTRESS) | Phase 1 | withdrawn | May 13, 2024 | Jules Bordet Institute | Sponsor decision | Sponsor / business decision |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated…(LOTIS-9) | Phase 2 | terminated | Dec 3, 2021 | ADC Therapeutics S.A. | The benefit-risk profile does not support continuation of the LOTIS-9 trial. | Other (stated, no rule matched) |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed…(EMBRACE) | Phase 2 | terminated | Nov 11, 2021 | Medical College of Wisconsin | Low enrollment. | Enrollment / accrual |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 22, 2022 | Ichnos Sciences SA | Business decision | Sponsor / business decision |
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After… | Phase 2 | terminated | Jan 13, 2022 | Alfred Chung, MD | Slow Accrual | Enrollment / accrual |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jan 28, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After… | Phase 2 | terminated | Dec 7, 2018 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Phase 1 | terminated | Jul 10, 2018 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05276622 | Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)(PaCE-MM) | — | terminated | Mar 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Investigator left the institution. | Investigator |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | Phase 2 | terminated | Mar 26, 2019 | Fondazione Italiana Linfomi - ETS | Study was halted prematurely due to safety, since tocity stopping rules have been met | Safety / toxicity |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Sep 22, 2023 | Kathleen Dorritie | Closure of trial per BMS | Other (stated, no rule matched) |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | Early Phase 1 | terminated | Jan 15, 2019 | Washington University School of Medicine | Drug formulation changed, opening new trial | Other (stated, no rule matched) |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 9, 2021 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL… | Phase 3 | terminated | Feb 9, 2021 | MEI Pharma, Inc. | Discontinuation of zandelisib program | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 25, 2025source: clinicaltrials